You are here

Pipeline Plus

Poor patient adherence is fueling keen interest in the development of drugs for glaucoma management. Several long-acting formulations of existing medications are in the early stages of development, as are new therapeutic classes such as guanylate cyclase activators.

Therapeutic options in development for the treatment of Crohn’s disease represent a broad range of approaches to this complex disease. This active pipeline contains a combination of both small-molecule entities and targeted monoclonal antibodies.

Despite failures in late-phase trials, the pipeline of medications for Alzheimer’s disease is robust as companies hope to be the first to bring an effective therapy to market. We review several investigational agents in late-stage development.

Upcoming antibacterial agents in the pipeline appear promising, but it is difficult to predict their long-term durability. This article focuses on investigational agents that target resistant gram-negative organisms commonly found in the health care setting.

Developing drugs with enhanced safety profiles and improving treatment affordability are vital for patients with MS. The author reviews some encouraging new agents in late-stage development.

The landscape of migraine therapy is set to change with the introduction of new classes of medications aimed at providing options for patients who have not responded to previous therapies. However, the pricing of the new agents will likely be a key determinant in the extent of their use in clinical practice.

We review the immunomodulatory agents in development for systemic lupus erythematosus, a relatively uncommon disorder affecting women of childbearing age.

We present immunotherapies, biosimilars, and molecular-targeted agents in late-stage development for patients with advanced colorectal cancer.

We present several novel drugs in development for enhancing cognition, treating negative symptoms, and providing improved options for treatment-resistant patients. Drug makers aim to enhance safety profiles and increase patient compliance to therapy.

Despite the many medications already available, patients with heart failure often have disease exacerbations, reduced quality of life, and increased mortality, highlighting the need for new treatment approaches. We explore drugs currently in development.

Analysts have identified several unmet needs in the HIV therapy marketplace. We present the promising candidates in late-stage clinical development or FDA review.

Tyrosine kinase inhibitors (TKIs) are leading systemic therapies for the treatment of renal cell carcinoma. However, programmed death-1 inhibitors, promising new agents in development, may surpass TKIs as the standard of care in the future.

Psoriasis, a disorder that manifests as a variety of chronic inflammatory skin diseases, affects an estimated 7.4 million Americans. We consider five promising biologic agents poised to enter the psoriasis market for advanced disease by 2019.

Vasculitis, a group of heterogeneous disorders characterized by inflammation and necrosis of the blood vessels, has but one treatment approved by the Food and Drug Administration. However, six novel biologic candidates are in late-stage development.

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most widespread and virulent nosocomial pathogens. The late-stage clinical pipeline includes an array of proposed new treatments aimed at MRSA-related skin infections and pneumonia.

Patients with type-2 diabetes can control their blood glucose levels through diet and exercise, by losing excess weight, and by taking medications, such as first-line metformin. We examine several promising drugs in the type-2 diabetes pipeline.

Analysts foresee substantial growth in the multiple myeloma market in the next decade, driven mainly by the monoclonal antibodies elotuzumab and daratumumab.

Agents are approved to treat exacerbations and symptoms and as disease-modifying therapy. Most therapies in the works would address relapsing forms of the disease.

Robust drug-development programs targeting the second most common male cancer (after skin cancer) will help increase U.S. market sales to $3.7 billion by 2023.

Life-threatening sepsis presents with varying symptoms due to the wide range of pathogens that cause it, and sepsis-specific treatment options for patients are sparse.

Potential blockbuster therapies, such as proprotein convertase subtilisin/kexin type 9 inhibitors, are expected to revolutionize dyslipidemia treatment and raise global sales.

As researchers seek more-effective, safer medications to treat human immunodeficiency virus, the focus has shifted to fixed-dose, single-tablet combinations.

Available options for Alzheimer’s disease are used only for symptomatic improvement, but disease-modifying therapies may help triple annual medication sales by 2023.

New Products Are Facing a Saturated Market

Major depressive disorder is complex and poorly understood; myriad drugs target numerous mechanisms of action. By 2023, sales are expected to reach $7.6 billion.

Future therapies for growth hormone deficiency are expected to include long-acting formulations that may encourage increased use of and adherence to these products.

New medications may soon offer more effective treatments for the approximately 2.5 million patients globally with schizophrenia. Current therapies in 2012 yielded $5.2 billion in global market sales, but by 2022 that is expected to reach $7.9 billion.

As new drugs emerge from the pipeline for the nearly 2 billion patients globally diagnosed with ulcerative colitis and Crohn’s disease, sales of therapies for these conditions are expected to increase from $7.35 billion today to $11.05 billion in 2022.

As better drugs from a variety of pharmaceutical industry players enter a market with millions of untreated patients, U.S. spending on hepatitis C treatments is expected to rise from $2.1 billion in 2012 to $6.5 billion in 2022.

Global prevalence of type-2 diabetes is expected to reach 330 million cases by 2022, with medication sales of $67.7 billion. The market is crowded with generic medications, and most products now in the development pipeline are “me-too” drugs.

The epilepsy market’s $4.2 billion in global sales in 2012 is expected to increase to $5.4 billion by 2022. In a market crowded with products, pharmaceutical companies have shifted their focus to devising safe adjunctive therapies for refractory patients.

Treatment of Parkinson’s disease is expected to lead to $3.56 billion in global sales in 2022. Manufacturers are reformulating medications in addition to creating new ones.